Benjamin Jackson CFA
Stock Analyst at Jefferies
(3.20)
# 4,410
Out of 12,268 analysts
82
Total ratings
55.8%
Success rate
6%
Average return
Main Sectors:
Stocks Rated by Benjamin Jackson CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: 0DPB Bavarian Nordic A/S | Maintained: Buy | $275 → $280 | $197.00 | +42.13% | 2 | May 19, 2026 | |
| EPA: IPN Ipsen S.A. | Maintained: Hold | $117 | $161.50 | -27.55% | 2 | May 17, 2026 | |
| SWX: GALD Galderma Group AG | Reiterated: Buy | $190 | $158.45 | +19.91% | 29 | Apr 23, 2026 | |
| ZLDPF Zealand Pharma A/S | Maintained: Buy | $505 | $50.26 | +904.78% | 2 | Apr 19, 2026 | |
| SWX: COPN Cosmo N.V. | Maintained: Buy | $150 → $140 | $78.90 | +77.44% | 2 | Mar 25, 2026 | |
| GMAB Genmab | Initiated Coverage: Buy | $42 | $26.88 | +54.42% | 1 | Feb 17, 2026 | |
| LON: 0MGB Genmab A/S | Initiated Coverage: Buy | $2,650 | $1,723.63 | +53.75% | 1 | Feb 16, 2026 | |
| SWX: NOVN Novartis AG | Maintained: Hold | $110 | $119.90 | -8.26% | 5 | Feb 4, 2026 | |
| EPA: SAN Sanofi | Maintained: Buy | $100 | $77.12 | +29.67% | 9 | Dec 29, 2025 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Sell | $415 → $290 | $289.00 | +0.35% | 7 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | $270 → $230 | $336.10 | -31.57% | 6 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $15 | $1,933.50 | -99.25% | 2 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $109 | $14,014.00 | -99.22% | 2 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $185 | $38.89 | n/a | 1 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6.8 | $5.02 | n/a | 10 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $3.8 | $3.03 | n/a | 1 | Oct 7, 2024 |
Bavarian Nordic A/S
May 19, 2026
Maintained: Buy
Price Target: $275 → $280
Current: $197.00
Upside: +42.13%
Ipsen S.A.
May 17, 2026
Maintained: Hold
Price Target: $117
Current: $161.50
Upside: -27.55%
Galderma Group AG
Apr 23, 2026
Reiterated: Buy
Price Target: $190
Current: $158.45
Upside: +19.91%
Zealand Pharma A/S
Apr 19, 2026
Maintained: Buy
Price Target: $505
Current: $50.26
Upside: +904.78%
Cosmo N.V.
Mar 25, 2026
Maintained: Buy
Price Target: $150 → $140
Current: $78.90
Upside: +77.44%
Genmab
Feb 17, 2026
Initiated Coverage: Buy
Price Target: $42
Current: $26.88
Upside: +54.42%
Genmab A/S
Feb 16, 2026
Initiated Coverage: Buy
Price Target: $2,650
Current: $1,723.63
Upside: +53.75%
Novartis AG
Feb 4, 2026
Maintained: Hold
Price Target: $110
Current: $119.90
Upside: -8.26%
Sanofi
Dec 29, 2025
Maintained: Buy
Price Target: $100
Current: $77.12
Upside: +29.67%
Novo Nordisk A/S
Oct 27, 2025
Maintained: Sell
Price Target: $415 → $290
Current: $289.00
Upside: +0.35%
Oct 27, 2025
Downgraded: Sell
Price Target: $270 → $230
Current: $336.10
Upside: -31.57%
Jul 30, 2025
Maintained: Hold
Price Target: $15
Current: $1,933.50
Upside: -99.25%
Jul 29, 2025
Maintained: Hold
Price Target: $109
Current: $14,014.00
Upside: -99.22%
Jan 31, 2025
Upgraded: Buy
Price Target: $185
Current: $38.89
Upside: n/a
Nov 13, 2024
Maintained: Hold
Price Target: $6.8
Current: $5.02
Upside: n/a
Oct 7, 2024
Downgraded: Hold
Price Target: $3.8
Current: $3.03
Upside: n/a